Reliq Health Technologies Inc V.RHT.H

FINANCIALS RELEASED / READ BELOW

[Humanist]

Reliq Health Technologies, Inc. Files Q2 FY2021 Financial Statements, Provides Corporate Update GlobeNewswire
 
Mar 01, 2021/ 7:34 pm

HAMILTON, Ontario, March 01, 2021 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (“Reliq” or the “Company”), a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market, announced that the interim consolidated financial statements (“Financial Statements”) and Management’s Discussion and Analysis (“MD&A”) for the quarter ended December 31, 2020, are now available on the Company’s profile on SEDAR (www.sedar.com). The Company is also pleased to provide the following corporate update.
As previously announced, Reliq will be hosting a
webinar tomorrow, March 2^nd at 6:00am PST / 9:00am
EST at https://bit.ly/37eU7rA. For those who are not able to attend the webinar, a recording of the webinar will be available on the Company’s website shortly after the session.   A written summary of the material updates to be presented in the webinar is also provided below.
Agenda for Webinar

1. Highlights from Q2 FY2021 interim consolidated financial statements
2. Outlook for Calendar Year 2021
3. Date for webinar to review Q3 FY2021 financials

1.   Highlights from Q2 FY2021 Financial Statements
      During the period ending December 31, 2020 and subsequent, the Company:

• Increased revenue by 108% quarter over quarter in Q2 FY2021 as compared to Q1 FY2021, in keeping with the Company’s guidance that revenue will increase every quarter throughout FY2021 and Calendar Year 2021.
•  
• Increased working capital significantly, from $938,892 as at June 30, 2020 to $2,092,136 as at December 31, 2020.
•  
• Increased gross margin to 54% in Q2 FY2021, as compared to 43% in Q1 FY2021 and 23% in Q2 FY2020. This is in keeping with the Company’s guidance that gross margin will increase every quarter through FY2021 and Calendar Year 2021, and is expected to reach approximately 75% by the end of Calendar Year 2021.
   
• Closed an oversubscribed, non-brokered private placement, issuing 13,493,332 units at a price of $0.225 per unit for gross proceeds of $3,036,000 (the “Units”). Each Unit consists of one common share and one-half of a share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable for an additional share at a price of $0.30 for a period of two years. In the event that the common shares of the Company trade at a closing price of greater than $0.50 per Share for ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to expire on the 30th day after the date on which such notice is given to the warrant holders. The Company paid finders’ fees of $48,782 cash and 188,775 broker warrants in connection with the financing. The broker warrants are issued with the same terms as the Warrants described above.
•  
• The proceeds of the raise are expected to take the Company through to profitability, which Management expects to achieve in Q4 FY2021 (quarter ending June 30, 2021).
•  
• If all of the Warrants from the private placement are exercised, the gross proceeds to the Company would be approximately $2,080,632.
•  
• Subsequent to December 31, 2020, received $808,500 in gross proceeds in Q3 FY2021 through the issuance of 3,250,000 common shares on the exercise of 3,250,000 stock options for gross proceeds of $748,500, and the issuance of 200,000 common shares on the exercise of 200,000 warrants for gross proceeds of $60,000.
•  
• Entered into a strategic alliance with iDocsWeb to offer the iUGO Care Platform to iDocsWeb’s more than 200 Skilled Nursing Facility (SNF) clients. Onboarding of patients began in December 2020.
•  
• Launched iUGO Well in Australia and signed a contract with the University of Notre Dame Australia to provide iUGO Well to their 12,000 faculty, staff and students. Onboarding began in Q2 FY2021 and is expected to continue to increase month over month throughout FY2021 and beyond.
•  
• Signed contracts and began onboarding patients with 15 new clients in Central and North Texas and Puerto Rico who will use Reliq’s proprietary iUGO Care Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Behavioral Health Integration (BHI) and Telemedicine platform.
•  
• Launched a new Annual Wellness Visit Support service and signed its first contract for the new service with a US client. This service helps Primary Care Providers complete Annual Wellness Visits (AWV) using Reliq’s iUGO Care Telemedicine platform and Care Management Center.
•  
• Signed its first contract to deploy its proprietary iUGO Home Solution. iUGO Home is a highly scalable solution that was designed to support patients in their own homes or in residential care settings such as long term care, skilled nursing and hospice facilities. The iUGO Home solution provides fall detection with automated alerts to the patient’s care team, medication reminders for the patient, two-way audio communication and automated geofencing-based alerts to the care team or family members if a patient wanders outside a defined area.
•  
• Launched a new multilingual Interactive Voice Recognition product, iUGO Care IVR, and signed a new contract with a physician practice in Maryland to use iUGO Care IVR with both their English- and Russian-speaking patients.
•  
• Signed a new contract with a Care Management Network in California that includes 50 Clinics and over 500 physicians. The network delivers culturally-customized, technology-enabled health care to senior citizens in the Asian-American community across California and will leverage Reliq’s customizable, multilingual iUGO Care and iUGO Home solutions to meet the needs of their Medicare, Medicaid and privately-insured patients.
•  
• Signed a new contract with a US Nephrology practice to use Reliq’s proprietary iUGO Care platform to monitor Chronic Kidney Disease (CKD) patients, demonstrating the flexibility of iUGO Care and its ability to help clinicians and patients manage virtually any complex chronic condition(s).
•  
• Initiated investor outreach programs to build awareness of the Company and its significant growth potential among potential investors, particularly in the US investment community. The Company engaged Lytham Partners for US Investor Relations and Wall Street Reporter for Investor Marketing.

2.   Outlook for Calendar Year 2021
The Company expects to achieve profitability in Q4 FY2021 (quarter ending June 30, 2021). Sales are expected to increase month over month every month throughout Calendar Year 2021. Growth is expected to accelerate significantly in the latter half of Calendar 2021 as COVID-19 vaccines become widely available and COVID-associated obstacles to onboarding are eliminated.

3.   Date for Next Quarterly Update Webinar
The Company’s interim consolidated financial statements for Q3 FY2021 (period ending March 31, 2021) are due to be filed on or before May 31, 2021. The webinar to review the financial statements will be scheduled on or before June 1, 2021.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director
 

[lscfa]

They dropped the guidance about being cash flow positive in March qtr but most investors assumed they would miss that. Not breaking down revenue is still distorting things. It looks like SAAS revenue grew 168% from last qtr. assuming no profit on device sales: Sept 2020 SAAS Devices Total Revenue

[Humanist]

iSCFA, IF I AM UNDERSTANDING YOU CORRECTLY, YOU'RE FEELING POSITIVE AS WELL.  OF COURSE WE PREFER EVEN BETTER NEWS. BUT IT APPEARS FINALLY EXECUTION IS HAPPENING AND WER'E MORE SOLID THAN WE'VE BEEN IN THE PAST 2 YRS?

[aaaaaargh]

About exactly as how I read it.  Saas revenue up which is the positive, guidance for this quarter dropped both in this report and in the recent webinars, said the same on the ceo site.

[teeswater]

thanks for summing up everyones comments Aaaaaaargh!

[butchtennis]

Good news.... 1. revenue increased 108% 2. margins increased to 54%... previously...43%... Basically, we should be going up!!

[theinvestor22]

Just a couple of quick, but I think important, points to highlight on your posting (see below).  Firstly, there was very good growth in SaaS.  Secondly, while I think it's still a bit early to get a firm handle on the underlying gross margin percentage for the SaaS part of the business, your calc points to a very high number (97%) for the quarter.

[mjh9413]

This is peanuts. ~1,300 clients. Nothing but a micro-cap...forever! eom

[lscfa]

More likely they still are not allocating any costs to the SAAS segment and the costs of devices includes something more than the inventory costs.   Dec 2020 SAAS Devices Total Revenue 218,022 199,792 417,814 Cost of

[theinvestor22]

Re the highlighted portion, I was thinking the exact same thing.  Over the coming quarters, GM% for SaaS should approach guided numbers and regular expenses should go down somewhat.

[Humanist]

did you have the chance to listen in on the webinar iscfa? if yes  whats' your impression? 

[lscfa]

Waste of time for the co. and listeners. Regurgitation of news releases. Better to ask questions at next Wall Street Reporter webcast.